Xiao Binyi, Peng Jianhong, Wang Yongchun, Deng Yuxiang, Ou Qingjian, Wu Xiaojun, Lin Junzhong, Pan Zhizhong, Zhang Lin
Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou, Guangzhou, China.
Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou, Guangzhou, China.
Ann Transl Med. 2020 Oct;8(19):1221. doi: 10.21037/atm-20-2762a.
The aim of this study was to assess the prognostic value of CD8+ tumor infiltrating lymphocytes (TIL) combined with programmed cell death-ligand 1 (PD-L1) expression for patients with solitary colorectal cancer liver metastasis (SCLM) undergoing R0 resection.
Patients undergoing curative hepatectomy for SCLM were reviewed. Immunohistochemical multiplex technique was used for quantifying CD8+ TIL, and immunohistochemical staining was used for assessing PD-L1 expression. The tumor immune microenvironment (TIME) was classified as strong for high CD8+ TIL and low PD-L1, weak for low CD8+ TIL and high PD-L1, and mild for the rest. Recurrence-free survival (RFS) and overall survival (OS) was compared between these groups.
Among the 94 patients included, a high CD8+ TIL and high PD-L1 expression was observed in 51 (54.3%) and 47 (50.0%) patients, respectively. Strong, mild, and weak TIME was observed in 24 (25.5%), 42 (44.7%), and 28 (29.8%) patients, respectively. Patients with a high CD8+ TIL had a significant longer RFS than patients with a low CD8+ TIL (3-year RFS rate, 71.6% 55.3%, P=0.018). The 3-year RFS rate in the strong TIME group was significantly higher than that in the mild and weak TIME groups (89.5% 71.7% and 28.8%, P<0.001), as was the 3-year rate of OS (93.8% 81.8% and 61.6%, P<0.001). CD8+ TIL combined with PD-L1 expression showed better predicting accuracy for RFS than CD8+ TIL alone.
The density of CD8+ TIL combined with PD-L1 expression in liver metastasis was a predictor of RFS for patients with SCLM undergoing R0 resection, and therefore can be used for guiding the postoperative treatment of these patients.
本研究旨在评估CD8 +肿瘤浸润淋巴细胞(TIL)联合程序性细胞死亡配体1(PD-L1)表达对接受R0切除的孤立性结直肠癌肝转移(SCLM)患者的预后价值。
回顾性分析接受SCLM根治性肝切除术的患者。采用免疫组织化学多重技术定量CD8 + TIL,并采用免疫组织化学染色评估PD-L1表达。肿瘤免疫微环境(TIME)根据CD8 + TIL高且PD-L1低分为强,CD8 + TIL低且PD-L1高分为弱,其余分为中度。比较这些组之间的无复发生存期(RFS)和总生存期(OS)。
在纳入的94例患者中,分别有51例(54.3%)和47例(50.0%)患者观察到高CD8 + TIL和高PD-L1表达。分别有24例(25.5%)、42例(44.7%)和28例(29.8%)患者观察到强、中、弱TIME。CD8 + TIL高的患者的RFS明显长于CD8 + TIL低的患者(3年RFS率,71.6%对55.3%,P = 0.018)。强TIME组的3年RFS率明显高于中度和弱TIME组(89.5%对71.7%和28.8%,P < 0.001),3年OS率也是如此(93.8%对81.8%和61.6%,P < 0.001)。与单独的CD8 + TIL相比,CD8 + TIL联合PD-L1表达对RFS的预测准确性更高。
肝转移中CD8 + TIL的密度联合PD-L1表达是接受R0切除的SCLM患者RFS的预测指标,因此可用于指导这些患者的术后治疗。